Metabolism of medroxyprogesterone acetate and hyper-coagulation
نویسندگان
چکیده
منابع مشابه
Subcutaneous depo-medroxyprogesterone acetate.
To cite: Cameron S. Journal of Family Planning and Reproductive Health Care 2013;39:75–77. INTRODUCTION Since 2004, a micronised formulation of depo-medroxyprogesterone acetate (DMPA) that is delivered as a subcutaneous injection has been available. It is currently in clinical use in the USA and in nine countries throughout Europe. As of March 2013 this product is being marketed in the UK as Sa...
متن کاملInjectable Medroxyprogesterone Acetate for Contraception
These guidelines reflect emerging clinical and scientific advances as of the date issued and are subject to change.The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions.They should be well documented if modified at the local level. None of the contents may be reproduced in an...
متن کاملDepot Medroxyprogesterone Acetate and Bone Density
The 2002 National Survey of Family Growth reported that 5.3% of all US women aged 15 through 44 currently using contraception used DMPA.1 Among contraceptors, 13.9% of those aged 15 to 19 and 10.1% of those aged 20 to 24 currently used DMPA compared with 1.6% of those aged 40 to 44.1 Decreasing rates of adolescent pregnancy between 1995 and 2002 are considered to be due in part to increased use...
متن کاملMedroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial☆☆☆
OBJECTIVE To describe medroxyprogesterone acetate (MPA) levels among Kenyan depot medroxyprogesterone acetate (DMPA) users in the FEM-PrEP HIV prevention trial, and to compare MPA levels between ARV for HIV prevention (treatment) and placebo groups. STUDY DESIGN We measured MPA in previously collected plasma samples from 63 Kenyan trial participants who used DMPA for one or two complete inter...
متن کاملHypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
A 39-year-old woman was admitted to our hospital with symptoms of general fatigue, nausea, and vomiting that appeared three months after she stopped seven years of medroxyprogesterone acetate (MPA) medication for endometrial stromal sarcoma. Laboratory tests demonstrated moderate hypercalcemia. Several tests demonstrated that she was suffering from adrenal insufficiency. Glucocorticoid suppleme...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Pharmacology
سال: 2000
ISSN: 0021-5198
DOI: 10.1016/s0021-5198(19)47873-6